NUCLEOTIDE SEQUENCES CODING FOR CRYPTOSPORIDIUM PROTEINS, POLYPEPTIDES CODED BY SAID SEQUENCES AND KITS FOR THE USE THEREOF

Abstract: Nucleic acids and polypeptides coded by said nucleic acids, derived from protozoan parasites of (Cryptosporidium) genus are described. Nucleic acids and peptides are advantageously used for developing detection assays of (Cryptosporidium) in biological samples of human and animal origin and/or in the environment.

Description: NUCLEOTIDE SEQUENCES CODING FOR CRYPTOSPORIDIUM PROTEINS, POLYPEPTIDES CODED BY SAID SEQUENCES AND KITS FOR THE USE THEREOF DESCRIPTION The invention concerns nucleic acids and polypeptides coded by said nucleic acids, derived from protozoan parasites of Cryptosporidium genus. Nucleic acids and peptides are advantageously used for developing detection assays of Cryptosporidium in biological samples of human and animal origin and/or in the environment. Cryptosporidium parasites infect the intestinal tract of several animal species. Over the last decade the number of infections in humans has dramatically increased. Most of the affected patients show a marked immunodeficiency, with a high incidence of AIDS. The immunocompromised patients develop a severe and frequently irreversible diarrhoea which causes malnutrition and represents a major factor leading to death. The prophylaxis of Cryptosporidium infections is hampered by the lack of reliable immunoassays for the detection of the parasite. Moreover, by microscopic examination, parasite oocyst are difficult to discriminate from several microoganisms that are morphologically similar to Cryptosporidium, like Candida species. The development of immunological and molecular diagnostic assays highly specific for Cryptosporidium absolutely requires the biochemical characterisation and localization of parasite antigens and the cloning of corresponding genes. The availability of diagnostic assays would permit to develop prophylactic measures for immunodeficient patients by detecting the parasites in the environment (food, water) and in individuals (relatives, nurses) that may act as carriers. Moreover, no effective therapeutic compounds against Cryptosporidium infection are available; therefore there is the need to develop reagents able to prevent the onset of the infection in im unodeficient patients. The authors of the present invention have obtained a rabbit antiserum raised against a whole lysate of Cryptosporidium oocysts. The serum has been used to screen a genomic library of Cryptosporidium from infected intestinal mucosal cells, into the expression vector λgtll. Among clones isolated, clone cpRL3 has been shown to comprise a 2359 bp (SEQ ID No.l) insert with an open reading frame coding for a polypeptide of 786 amino acids (SEQ ID No.2) . Scanning of the 67.0 version of the "GENE BANK" data base using the cpRL3 sequence failed to reveal any similarity with known DNA sequences. The cpRL3 insert has been subcloned into an expression plasmid and the corresponding recombinant polypeptide is produced in E. coli , fused at the N-terminus to a stretch of six histidines. The histidine sequence allows a fast and efficient purification by nickel chelate chromatography of the polypeptide encoded by cpRL3. The recombinant polypeptide is used as immunogen in Balb/c mice for producing antisera and monoclonal antibodies. The recombinant protein is highly immunogenic. This sequence codes for a portion of a protein of the oocyst wall of Cryptosporidium that has an apparent molecular weight of 190, 000 Dalton, named "Cryptosporidium Oocyst Wall Protein" (COWP) . Nucleotide and polypeptide sequences derived from the isolated sequence are advantageously utilized for diagnosis of Cryptosporidium infections in patients and/or animals and for analysis of environmental contamination by Cryptosporidium oocysts. Treatment of ' Cryptosporidium infection may be obtained by administration of antibodies raised against COWP. The invention concerns also: - designing of specific oligonucleotides, as primers in polymerase chain reactions (PCR) reactions for the detection of the COWP DNA sequence; - the utilisation of COWP amino acid sequence or fragments thereof to raise antisera and/or monoclonal antibodies for the development of immunological assays to detect the presence of Cryptosporidium and/or COWP molecule; - the use of COWP derived polypeptides, either synthetic or recombinant, as components of diagnostic kits for the detection of COWP released by parasites; - the utilisation of COWP-derived polypeptides, either synthetic or recombinant, for producing antisera and/or monoclonal antibodies to be employed in the therapy of Cryptσsporidiosis . It is a specific object of the present invention a polypeptide in a substantially purified form comprising a contiguous sequence coded by a Cryptosporidium gene, said gene comprising a nucleotide sequence at least 50 % homologous to the sequence of SEQ ID No.l. Preferably said contiguous sequence comprises an antigenic determinant of Cryptosporidium. More preferably said contiguous sequence is coded by the sequence of SEQ ID No.l, or parts thereof; most preferably said contiguous sequence is comprised in the aminoacid sequence of SEQ ID No.2. It is another object of the invention a diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, the polypeptide according to the invention. It is another object of the invention the use of a polypeptide according to the invention for raising ' antibodies able to detect Cryptosporidium infection in biological and environmental samples. It is another object of the invention an antibody obtained using as immunogen a polypeptide according to the invention. It is another object of the invention a diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, an antibody able to react with at least one polypeptide according to the invention. It is another object of the invention an oligonucleotide derived from a Cryptosporidium gene, said gene comprising a sequence at least 50 % homologous to the sequence of SEQ ID No.l. Preferably said oligonucleotide has a sequence comprised in the sequence of SEQ ID No.l, or in the complementary sequence of SEQ ID No.l. It is another object of the invention a diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, the oligonucleotide according to the invention. It is another object of the invention a PCR kit for the amplification of Cryptosporidium DNA comprising, as specif primer, at least one oligonucleotide according to the invention. Preferably said PCR kit comprises two oligonucleotides having nucleotide sequences according to the invention. The invention will be illustrated in the following examples, by making reference to the following figures, wherein: - Figure 1 shows an immunoblot analysis of the mouse serum (M10/01) (A) and of a control mouse serum anti TRAP (B) against: the expression product of the control plasmid pDS56/RBSII-E-6his-TRAP purified on nickel column (1) ; the expression product of the ' plasmid pDS56/RBSII-E-6his-cpRL3 purified on nickel column (2) ; a protein lysate of E. coli cells transformed with pDS56/RBSII-E-6his-cpRL3 induced with IPTG (3); and non induced (4); molecular weight standard are indicated. - Figure 2 shows an immunoblot analysis using the mouse serum MlO/01 (A) and the MAbl IB2 (B) against a protein lysate of C. parvum oocysts. - Figure 3A shows an electrophoresis of PCR products amplified from C. parvum DNA (1; 4) and from DNA of the plasmid pDS56/RBSII-E-6his-cpRL3 (2;5) using primers combinations Cry-3/Cry-6 (1;2) or Cry-5/Cry-6 (3;4;5;). As control, PCR reaction without template DNA (3) . Figure 3B shows an electrophoresis of PCR products amplified from DNA of several parasite species using primer combination Cry-3/Cry-6: DNA extracted from: C. parvum (1), Sarcocystis sp. (2), Giardia lamblia (3) and P. falciparum (4) . Figure 3C shows an electrophoresis of PCR products amplified from DNA of progressively diluted C. parvum oocysts using the primer combinations Cry-3/Cry-6: molecular standards (1), 160 oocysts (2), 80 oocysts (3), 40 oocysts (4), 20 oocysts (5) 10 oocysts (6) . As control, PCR reaction is done without template DNA (7) or in the presence of P. falciparum DNA (8) . In panels A, B and C, lanes β, 5 and 1 respectively, DNA markers are 3611; 1166; 606; 517; 396; 318; 263 bp. Example 1 λgtll library with DNA extracted from C. parvum infected calf intestinal mucosa To develop a C. parvum genomic expression library, DNA extracted from the intestinal mucosa of an infected calf is used. A newborne calf is infected with 6 x 10 8 oocysts of C. parvum MI ISS-1 (Pozio et al. 1992. Trans. R. Soc. Trop. Med. Hyg. 86:636-038) . After 5 days, the gut is opened, cut into segments of 30 cm ' each and washed in phosphate-buffered saline (PBS) . Nitro-cellulose filters (soaked in PBS) of the same size as the gut segments are applied to the mucosal side for a few seconds. Filters are progressively numbered and processed for DNA extraction. A small sample is removed from each filter and analysed by microscopy to determine whether parasites have been removed. The sample from each filter is incubated with 1% glutaraldehyde in cacodylate buffer for 2 h. The filters are dehydrated through an increasing ethanol series, embedded in Epon, and cured at 60°C for 24 h. Sections are cut at 0.2-μm thickness and stained with toluidine blue. The analysis reveals that nitro¬ cellulose filters remove only the superficial layer of mucosal cells, together with a large number of parasites. Only DNA extracted from filters that have removed a large number of parasites are used. DNA is digested with EcoRI and cloned in λgtll EcoRI digested, 3' end to the coding sequence of /3-galactosidase gene. Phage DNA with cloned inserts is packaged in vi tro (Boehringer Mannheim in vi tro packaging kit) to generate the library. The quality of the library is evaluated by analysing the sizes of a subset of inserts by polymerase chain reaction (PCR) with oligonucleotides corresponding to the flanking sequences of the EcoRI site of the β-galactosidase gene. The library has a complexity of 4.5 X 10 6 plaques and an estimated average insert size of 1,800 bp. The expression library is analysed by use of a rabbit serum developed against purified oocysts of C. parvum MI ISS-1. The serum is used after removal of the background reactivity by several absorptions on filters soaked with bacterial and phage lysates. Specific antibodies bound to filters are detected by use of a second anti-rabbit antibody conjugated to alkaline " phosphatase. An insert, named cpRL3, consisting of a 2,359-bp open reading frame encoding a polypeptide of 786 amino acids, is isolated. The lack of both a start codon and a stop codon indicates that the sequence represents part of the coding sequence of the isolated parasitic gene. Example 2 Expression of the cpRL3 sequence in E. coli The DNA insert cpRL3 is cloned in the EcoRI site of plasmid pDS56/RBSII-E~ 6xHis (a pDS56/RBSII derived plasmid containing an EcoRI site in the polylinker) . The expression unit of this vector is under the control of an isopropyl-/3- thiogalactopyranoside (IPTG)-inducible promoter and yields a fusion between a stretch of 6 histidines and the amino terminus of the inserted sequences (Stuber et al. 1990, Eur. J. Immunol 20:819-824). cpRL3 is expressed in E. coli M15 carrying the lac repressor-producing plasmid pUHAl. Induction is performed in LB medium for 4 h at 37°C; 1 mM IPTG is added when the cell density reaches an optical density at 600 n of 0 6. Example 3 Purification of recombinant polypeptide 6x His-cpRL3 The expression product of the cpRL3 sequence (recombinant polypeptide 6xHis-cpRL3) is purified in a single-step procedure, by nickel chelate affinity chromatography (Stuber et al., ibid.). In brief, one litre of an induced culture of M15(pUHAl) cells carrying plasmid pDS56/RBSII-E-6xHis-cpRL3 is harvested and stirred for 3 h in 100 ml of 6 M guanidine hydrochloride, 100 mM Na2HPθ4, pH 8. The suspension is centrifuged at 10,000 x g, and the supernatant is directly applied to a nickel column (NTA-resin, Diagen) . After an equilibration step with 8 M urea, 100 mM NaH2Pθ4, 10 mM Tris, pH 8, 6xHis-cpRL3 is eluted by lowering the pH of the urea solution stepwise to pH 4. " From one litre of culture, 1 mg of 6xHis-cpRL3 is obtained. Example 4 Immunoblotting Parasite lysates are obtained from Cryptosporidium oocysts purified by Percoll gradient centrifugation (Waldman, E., et al. 1986. J. Clin. Microbiol. 23:199-200). Parasites are lysed by incubation of pellet of 2 x 10^ oocysts with 0.2 ml of sample buffer (33 mM Tris-HCl, pH 6.8, 190 mM glycerol, 0.1% SDS) . Bacterial lysates are obtained by treatment of 10 9 induced or non induced E. coli cells with 1 ml of sample buffer. Proteins in total cell lysates are separated by SDS-polyacrylamide gel electrophoresis (PAGE) (Laemmli,U.K. 1970. Nature (London) 227:680-685) and electroblotted onto nitro-cellulose filters (blotting buffer, 25 mM Tris, 192 mM glycine, 20% methaπol) . Non-specific adsorption of antibodies to the nitro-cellulose is prevented by saturation of the filters with 1% bovine serum albumin in 2x TBST (20 mM Tris-HCl, pH 8, 300 mM NaCl, 0.1% Tween 20) for 2 h at room temperature. Nitrocellulose filters are incubated with antibodies for 2 h at room temperature. After extensive washing with 2x TBST, antibodies bound to the filters are detected by use of goat anti-mouse immunoglobulin (heavy and light chains) conjugated to alkaline phosphates (Promega) . Phosphatase activity is disclosed by incubation of the filters with 0.3 mg of Nitro Blue Tetrazoliu and 0.15 mg of 5-bromo 4-chloro-3-indolyl phosphate per ml in 100 mM Tris-HCl (pH 9.5)-100 mM NaCl-5 mM MgCl . Example 5 Monoclonal antibody production After purification by nickel chelate chromatography, recombinant polypeptide 6xHis-cpRL3 is used as immunogen to develop specific antisera and monoclonal antibodies. BALB/c mice are immunised three times with 50 μg of purified 6xHis-cpRL3 polypeptide in complete (for the first immunisation) or incomplete Freund's adjuvant. Five days after the last immunisation, mouse spleen cells are fused with x63 Ag 8653 myeloma cells and subsequently screened for antibody production (Kohler,G. and C. Milstein 1975 Nature (London) 256:495-497). The supernatants of cultures from growing hybrids are tested in an enzyme-linked immunosorbent assay (ELISA) against 6xHisCpRL3. Immunised mice develop an antibody titer of 1/500,000. Figure 1 (A and B) shows the ability of one of the antisera to recognise specifically by immunoblot the recombinant polypeptide encoded by cpRL3. The antiserum recognises the recombinant polypeptide in a total lysate of bacteria in which the expression of the cpRL3 insert is induced with IPTG (Fig. 1A, lane 3) . The antiserum also recognize the polypeptide after purification by the nickel chelate chromatography. The specificity of the reaction is demonstrated by the lack of reactivity against E. coli proteins, as well as against an unrelated recombinant protein, TRAP, expressed from the control plasmid pDS56/RBSII-6xHis (TRAP) , also sharing the six histidine amino-terminal tail. Antibodies developed against the expression product of insert cpRL3 (mouse antiserum and monoclonal antibody 2B11) detect, in the lysate of Cryptosporidium oocysts, a protein of the apparent molecular weight of 190,000 Dalton, (Figure 2 A and B) . These results indicates that the expression product of the insert cpRL3 is part a Clyptosporidium protein expressed in the parasite oocysts. Example 6 Immunofluorescence microscopy Purified parasite oocysts are air dried on a coverslip and fixed in cold acetone for 5 min. Non- specific binding is prevented by pre-incubation of the samples in PBS containing 1% bovine albumin. Primary " antibodies (culture supernatant) are allowed to react for 40 min at room temperature, and the secondary fluorescinated antibody (Becton Dickinson goat anti-mouse) is allowed to react for 20 min. Observation of the samples is carried out with confocal microscopic apparatus (Bio-Rad Laboratories) . The protein is localised by immunofluorescence using the monoclonal antibody 2B11 on a preparation of oocysts fixed with acetone. The monoclonal 2B11 specifically binds to a protein of oocyst wall of Cryptosporidium. The result of the immunolocalization is confirmed by confocal immunofluorescence analysis which shows that the reactivity is detected on the surface of the oocyst wall. On the basis of these observations, the Cryptosporidium protein encoded by the insert cpRL3 is named as Cryptosporidium oocyst wall protein, COWP. By immunofluorescence, monoclonal antibodies can identify as few as 100 oocysts/ml of stools. The detection limit of this method is determined resuspending known numbers of oocysts in samples of non infected stools. Example 7 ELISA assays Monoclonal antibodies produced against the product of the insert cpRL3 are able to recognise COWP in solution when used in ELISA assays based on antigen capture with two antibodies. Therefore specific antibodies directed against this protein or fragments thereof having an antigenic activity, as the product of cpRL3, can be employed to develop diaσnostic assay to reveal Cryptosporidium infection. Example 8 PCR For all PCR experiments, the cpRL3 sequence is amplified in a standard 50 μl PCR reaction mixture (Saiki, R K., et al. 1988. Science 239:487-491; Scharf, S. J. et al. 1986. Science 233:1076-1078) for 35 cycles ' at 94,5°C (1 min), 58°C (30 sec); 72°C(1 min), with a Lab Line thermal cycler. The final concentration of MgCl is 2 mM. Primers used are: Cry3 (5'GTCCTACTGGATTCACTCTAC-3') coding strand, nt.722-742 of SEQ ID No. 1; Cry5 (5'-CCAGGACATCATCATGGTCATTCTCATGGGC-3' ) coding strand, nt. 1099-1129 of SEQ ID No. 1; Cry6 (5'-CCGAATATGTAACACATTTATCCGC-3 T ) non coding strand, nt. 1828-1852 of complementary strand of SEQ ID No. 1. For amplification of the cpRL3 sequence from Cryptosporidium oocysts, samples are incubated for 5 min under reducing conditions and boiled for 10 min thereafter. Taql polymerase is purchased from Perkin-Elmer Co. The ability of two oligonucleotide combinations to amplify by PCR the sequence of cpRL3 is shown in Figure 3A. Both of oligonucleotide combinations Cry3/Cry6 and Cry5/Cry6 are able to amplify DNA segments of the expected molecular weight from the plasmid pDS56/RBSII-E-6xHis (cpRL3) and from DNA of Cryptosporidium. The amplification reaction using oligonucleotides Cry3/Cry6 is highly specific, (figure 3B) . Oligonucleotides in fact do not amplify any DNA segment when DNA of other protozoa ( Giardia lamblia, Plasmodium falciparum o Sarcocystis suis hominis) is used as template. In PCR experiments the oligonucleotide combination Cry3/Cry6 is able to amplify a specific DNA segment from as few as 40 oocysts of Cryptosporidium, (Figure 3C) . These data indicate that by using combination of oligonucleotides corresponding different regions of cpRL3 sequence, PCR can be employed to detect the presence of Cryptosporidi urn . SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Universita' degli Studi di Roma "La Sapienza" (B) STREET: P.le Aldo Moro 5 (C) CITY: Rome (E) COUNTRY: Italy (F) POSTAL CODE (ZIP) : 00185 (A) NAME: Istituto Superiore di Sanita' (B) STREET: V.le Regina Elena 299 (C) CITY: Rome (E) COUNTRY: Italy (F) POSTAL CODE (ZIP) : 00161 (ii) TITLE OF INVENTION : Nucleotide sequences coding for Cryptosporidium proteins, polypeptides coded by said sequences and kits (iii) NUMBER OF SEQUENCES: 2 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Cryptosporidium parvum (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2359 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GAA TTC GAA TGC CCA CCA GGT ACA ATT TTA AAA GAT GAT CAA TGT CAA 48 Glu Phe Glu Cys Pro Pro Gly Thr lie Leu Lys Asp Asp Gin Cys Gin 1 5 10 15 TCG ATA GAA AGA GTT GAT ACA ATT TGT CCA CCA GGG TTT GTA GAT AAT 96 Ser lie Glu Arg Val Asp Thr lie Cys Pro Pro Gly Phe Val Asp Asn 20 25 30 GGC GAA GAT TGT GTC CAA TTT TCT GCA CCA GAG AAA ATT TGC CCC CAA 144 Gly Glu Asp Cys Val Gin Phe Ser Ala Pro Glu Lys lie Cys Pro Gin 35 40 45 GGA TTT TCT CTT TCC GGA AAA CAA TGT GTT AAA ACA GAA TCT GCT CCA 192 Gly Phe Ser Leu Ser Gly Lys Gin Cys Val Lys Thr Glu Ser Ala Pro 50 55 60 AGA TTA ACA GAA TGC CCA CCA GGT ACA ACC TTG GAA AAT AAC AGT TGT 240 Arg Leu Thr Glu Cys Pro Pro Gly Thr Thr Leu Glu Asn Asn Ser Cys 65 70 75 80 ATT TCA TAT GAA CTA GAA GAT GCC ATT TGT CCA CCT GGA TAT CTC GAC 288 lie Ser Tyr Glu Leu Glu Asp Ala lie Cys Pro Pro Gly Tyr Leu Asp 85 90 95 AAT GGA TCA GAC TGT GTT CAG TTT TCT CAA CCA GAA AAG GAG TGT CCA 336 Asn Gly Ser Asp Cys Val Gin Phe Ser Gin Pro Glu Lvs Glu Cys Pro 100 105 " 110 ACA GGT TTT GTA TTA ATT GGA AAA CAA TGT ACC CAA ACT ACT CAA GCT 384 Thr Gly Phe Val Leu lie Gly Lys Gin Cys Thr Gin Thr Thr Gin Ala 115 120 125 CCA CCA CAA CCA GAG TGT CCT CCA GGT ACA AAC CTG GTA AAT GGA CAA 432 Pro Pro Gin Pro Glu Cys Pro Pro Gly Thr Asn Leu Val Asn Glv Gin 130 135 140 TGC CAA AAA GTT GAA AGG ATA AAT ATG GTA TGT CCA ACT GGT TTT ATT 480 Cys Gin Lys Val Glu Arg lie Asn Met Val Cys Pro Thr Gly Phe lie 145 150 155 160 GAT AAT GGT ACA AAT TGT GCT TCT TTC TCC GCA CCA AAC AGA GAA TGC 528 Asp Asn Gly Thr Asn Cys Ala Ser Phe Ser Ala Pro Asn Arg Glu Cys 165 170 175 CCA CCT GGA TAT ACA CTT TCT GGA TCC CAA TGC GAG CAA ATA AAA GAA 576 Pro Pro Gly Tyr Thr Leu Ser Gly Ser Gin Cys Glu Gin lie Lys Glu 180 185 190 GCA CCT CCT GTT TCA GAA TGT CCA CCA GGA TAT AAA CTT CAA GGA AAT 624 Ala Pro Pro Val Ser Glu Cys Pro Pro Gly Tyr Lys Leu Gin Gly Asn 195 200 205 CAA TGT ACT GCA CTA AAA ATG ATC GAT GCT ATC TGC CCA GAT GGA TTT 672 Gin Cys Thr Ala Leu Lys Met He Asp Ala He Cys Pro Asp Gly Phe 210 215 220 TTA CCA AAT GGA GAC GAT TGT ATC CAA TTT TCT CCT GCT TCA ACT GTA 720 Leu Pro Asn Gly Asp Asp Cys He Gin Phe Ser Pro Ala Ser Thr Val 225 230 235 240 TGT CCT ACT GGA TTC ACT CTA CAA AAT CAA CAG TGT GTT CAA ACA ACT 768 Cys Pro Thr Gly Phe Thr Leu Gin Asn Gin Gin Cys Val Gin Thr Thr 245 250 255 ACC TCA CCA AAA ACA CCA GAA TGT CCT CCA GGT TCT GCG TTG GAT GGA 816 Thr Ser Pro Lys Thr Pro Glu Cys Pro Pro Gly Ser Ala Leu Asp Gly 260 265 270 GAC TCG TGC ACA AGA CTT GTT CCC GGG GCT CTT CAA TAC GTT TGT CCT 864 Asp Ser Cys Thr Arg Leu Val Pro Gly Ala Leu Gin Tyr Val Cys Pro 275 280 285 GTT GGT ACT AGA GAG GGG GAC GTT TGC GTA GAG AGA TCG ATT AGT TCG 912 Val Gly Thr Arg Glu Gly Asp Val Cys Val Glu Arg Ser He Ser Ser 290 295 300 CCT GTT TTG GAA TGC CCA CCT GGT TAT TCA TTG GAA ACA GGT AAA CAA 960 Pro Val Leu Glu Cys Pro Pro Gly Tyr Ser Leu Glu Thr Gly Lys Gin 305 310 315 320 TGT GTT AGA AGA AGC CAA TAT GAC TGT TCA GTA ACA ACT TAT GTT ACA 1008 Cys Val Arg Arg Ser Gin Tyr Asp Cys Ser Val Thr Thr Tyr Val Thr 325 330 335 GAG TGT AAA ACA CCT GAT GTT AAA GCA CTA AGA AGA TTA GCA GCT GCA 1056 Glu Cys Lys Thr Pro Asp Val Lys Ala Leu Arg Arg Leu Ala Ala Ala 340 345 350 AAA GAA ACA TCA ACA GTT TAT GAA ACA TCT GAG ATA CAA AAT CCA GGA 1104 Lys Glu Thr Ser Thr Val Tyr Glu Thr Ser Glu He Gin Asn Pro Gly 355 360 365 CAT CAT CAT GGT CAT TCT CAT GGG CAT TCA CAT TCA CAA GTT ATA CCA 1152 His His His Gly His Ser His Gly His Ser His Ser Gin Val He Pro 370 375 380 ATT CAA ACC CAG AAT ATA CAT ACA CAA CAT CAT AAA GAG GCT CCA AGG 1200 He Gin Thr Gin Asn He His Thr Gin His His Lys Glu Ala Pro Arg 385 390 395 400 CCA ATT TGT GAA GAT GTT CCA AAA ATT ACC CCA AAA ACT TGT ACA AAA 1248 Pro He Cys Glu Asp Val Pro Lys He Thr Pro Lys Thr Cys Thr Lys 405 410 415 GCT GAT TCT GTC CCA GCT GTG CCT ATT TGC GAG AAC AAT GCT GAA CTT 1296 Ala Asp Ser Val Pro Ala Val Pro He Cys Glu Asn Asn Ala Glu Leu 420 425 430 GTA GGA AAA GAA TGT GTA TTA ACA AAT TAC TAC CCA TTA GAA GCA ATT 1344 Val Gly Lys Glu Cys Val Leu Thr Asn Tyr Tyr Pro Leu Glu Ala He 435 440 445 TGT CAA GAT GGA ACA AGA TCA AAA GAG TGT GCT AAG TTT GTA AAA ACT 1392 Cys Gin Asp Gly Thr Arg Ser Lys Glu Cys Ala Lys Phe Val Lys Thr 450 455 460 CCA CCT ACT TTA AAA TGT CCG CCA GGT TCT GTA GAT GTA GGA TCT CAA 1440 Pro Pro Thr Leu Lys Cys Pro Pro Gly Ser Val Asp Val Gly Ser Gin 465 470 475 480 TGT CAA GTT AAC AAA TAT TCA CCA TAT GAT CTT GCA TGC CCT GCA GGA 1488 Cys Gin Val Asn Lys Tyr Ser Pro Tyr Asp Leu Ala Cys Pro Ala Gly 485 490 495 TAT GCA TTG GTT GGA GAC AAA TGC GCT ACC ACA AGA GAA AAA GTT TGC 1536 Tyr Ala Leu Val Gly Asp Lys Cys Ala Thr Thr Arg Glu Lys Val Cys 500 505 510 CCG AAT GAA AGT TGC CAA AGA GTT GTA ACT GCG CCT GTT TCT TTA ACT 1584 Pro Asn Glu Ser Cys Gin Arg Val Val Thr Ala Pro Val Ser Leu Thr 515 520 525 TGT CCC CCT GGA TAT CAC CAA ATA GAT GAA GTT ATG AAT ATT TCT GCT 1632 Cys Pro Pro Gly Tyr His Gin He Asp Glu Val Met Asn He Ser Ala 530 535 540 CAT CCA CAC CAC AGA CAC TTA GCT GGG GTT CAA TCT ACT TCT CAA AAG 1680 His Pro His His Arg His Leu Ala Gly Val Gin Ser Thr Ser Gin Lys 545 550 555 560 GGA TAT TCT CAT GGA CAT AAA TAT ACT CCT GTA ATT TCT CAG CCA CCA 1728 Gly Tyr Ser His Gly His Lys Tyr Thr Pro Val He Ser Gin Pro Pro 565 570 575 CAA CCA GTT CCA GTT GTT GCT CCT ATT CAG CAA ATG AAA TGC ATC CAT 1776 Gin Pro Val Pro Val Val Ala Pro He Gin Gin Met Lys Cys He His 580 585 590 GCA AAC CAT GCT CCA TAT AAT CTT ATC TGT CCT GTT GGA TCA AGA CTT 1824 Ala Asn His Ala Pro Tyr Asn Leu He Cys Pro Val Gly Ser Arg Leu 595 600 605 GTA GCG GAT AAA TGT GTT ACA TAT TCG GAT AAA ATA TGT CCA AAT GGT 1872 Val Ala Asp Lys Cys Val Thr Tyr Ser Asp Lys He Cys Pro Asn Gly 610 615 620 AAT TGC GAG CGT ATA TAT AAT GAG CCT GCT GAA TTA GTA TGC CCT CCA 1920 Asn Cys Glu Arg He Tyr Asn Glu Pro Ala Glu Leu Val Cys Pro Pro 625 630 635 640 GGA TTC TCA TCA TCT AAA CCA ATT CAG CCA ATA AGC CAT TCT CAT ATT 1968 Gly Phe Ser Ser Ser Lys Pro He Gin Pro He Ser His Ser His He 645 650 655 AAC CAT CCA AAT GTT TCT GTT CCC GTC CAA CCA CAA ACT ATT AAC CAA 2016 Asn His Pro Asn Val Ser Val Pro Val Gin Pro Gin Thr He Asn Gin 660 665 670 CCA CAA GTA ATT CAA CAA AGA CAA GTA AAT TAT CAG CCA CAA GTA ATT 2064 Pro Gin Val He Gin Gin Arg Gin Val Asn Tyr Gin Pro Gin Val He 675 680 685 CAT CAA ACA CAG GAA ATT TTA ACA ACT TAT CCA ACT CCA GTT TAC CAA 2112 His Gin Thr Gin Glu He Leu Thr Thr Tyr Pro Thr Pro Val Tyr Gin 690 695 700 ACC GGC ACA ATT TAT CAA GGA CAT CAT CAT CAT CAT CAT CAT CAT CAC 2160 Thr Gly Thr He Tyr Gin Gly His His His His His His His His His 705 710 715 720 AGA AAT CTA GCT TCC CCT GAG TGC ATT AAG ACA ATT TCA GTA CCT TAT 2208 Arg Asn Leu Ala Ser Pro Glu Cys He Lys Thr He Ser Val Pro Tyr 725 730 735 ATT TTA AAA TGC GAA TCT CCA TTT ATT TTA GAT GGC GAC AAA TGT ATC 2256 He Leu Lys Cys Glu Ser Pro Phe He Leu Asp Gly Asp Lys Cys He 740 745 750 GAA AAA ACA GAA AAA ATT TGT CTA CAA GGT GAC TGC AGA AAA CAA GTC 2304 Glu Lys Thr Glu Lys He Cys Leu Gin Gly Asp Cys Arg Lys Gin Val 755 760 765 GTC GTT CCA CCA ACT CTT TCA TGT CCA CAA GGT TAC AGA AAT GCC AAC 2352 Val Val Pro Pro Thr Leu Ser Cys Pro Gin Gly Tyr Arg Asn Ala Asn 770 775 780 GGA ATT C 2359 Gly He 785 (2) INFORMATION FOR SEQ ID NO: 2: (ij SEQUENCE CHARACTERISTICS: (A) LENGTH: 786 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Glu Phe Glu Cys Pro Pro Gly Thr He Leu Lys Asp Asp Gin Cys Gin 1 5 10 15 Ser He Glu Arg Val Asp Thr He Cys Pro Pro Gly Phe Val Asp Asn 20 25 30 Gly Glu Asp Cys Val Gin Phe Ser Ala Pro Glu Lys He Cys Pro Gin 35 40 45 Gly Phe Ser Leu Ser Gly Lys Gin Cys Val Lys Thr Glu Ser Ala Pro 50 55 60 Arg Leu Thr Glu Cys Pro Pro Gly Thr Thr Leu Glu Asn Asn Ser Cys 65 70 75 80 He Ser Tyr Glu Leu Glu Asp Ala He Cys Pro Pro Gly Tyr Leu Asp 85 90 95 Asn Gly Ser Asp Cys Val Gin Phe Ser Gin Pro Glu Lys Glu Cys Pro 100 105 110 Thr Gly Phe Val Leu He Gly Lys Gin Cys Thr Gin Thr Thr Gin Ala 115 120 125 Pro Pro Gin Pro Glu Cys Pro Pro Gly Thr Asn Leu Val Asn Gly Gin 130 135 140 Cys Gin Lys Val Glu Arg He Asn Met Val Cys Pro Thr Gly Phe He 145 150 155 160 Asp Asn Gly Thr Asn Cys Ala Ser Phe Ser Ala Pro Asn Arg Glu Cys 165 170 175 Pro Pro Gly Tyr Thr Leu Ser Gly Ser Gin Cys Glu Gin He Lys Glu 180 185 190 Ala Pro Pro Val Ser Glu Cys Pro Pro Gly Tyr Lys Leu Gin Gly Asn 195 200 " 205 Gin Cys Thr Ala Leu Lys Met He Asp Ala He Cys Pro Asp Gly Phe 210 215 220 Leu Pro Asn Gly Asp Asp Cys He Gin Phe Ser Pro Ala Ser Thr Val 225 230 235 240 Cys Pro Thr Gly Phe Thr Leu Gin Asn Gin Gin Cys Val Gin Thr Thr 245 250 255 Thr Ser Pro Lys Thr Pro Glu Cys Pro Pro Gly Ser Ala Leu Asp Gly 260 265 270 Asp Ser Cys Thr Arg Leu Val Pro Gly Ala Leu Gin Tyr Val Cys Pro 275 280 285 Val Gly Thr Arg Glu Gly Asp Val Cys Val Glu Arg Ser He Ser Ser 290 295 300 Pro Val Leu Glu Cys Pro Pro Gly Tyr Ser Leu Glu Thr Gly Lys Gin 305 310 315 320 Cys Val Arg Arg Ser Gin Tyr Asp Cys Ser Val Thr Thr Tyr Val Thr 325 330 335 Glu Cys Lys Thr Pro Asp Val Lys Ala Leu Arg Arg Leu Ala Ala Ala 340 345 350 Lys Glu Thr Ser Thr Val Tyr Glu Thr Ser Glu He Gin Asn Pro Gly 355 360 365 His His His Gly His Ser His Gly His Ser His Ser Gin Val He Pro 370 375 380 He Gin Thr Gin Asn He His Thr Gin His His Lys Glu Ala Pro Arg 385 390 395 400 Pro He Cys Glu Asp Val Pro Lys He Thr Pro Lys Thr Cys Thr Lys 405 410 415 Ala Asp Ser Val Pro Ala Val Pro He Cys Glu Asn Asn Ala Glu Leu 420 425 430 Val Gly Lys Glu Cys Val Leu Thr Asn Tyr Tyr Pro Leu Glu Ala He 435 440 445 Cys Gin Asp Gly Thr Arg Ser Lys Glu Cys Ala Lys Phe Val Lys Thr 450 455 460 Pro Pro Thr Leu Lys Cys Pro Pro Gly Ser Val Asp Val Gly Ser Gin 465 470 475 480 Cys Gin Val Asn Lys Tyr Ser Pro Tyr Asp Leu Ala Cys Pro Ala Gly 485 490 495 Tyr Ala Leu Val Gly Asp Lys Cys Ala Thr Thr Arg Glu Lys Val Cys 500 505 510 Pro Asn Glu Ser Cys Gin Arg Val Val Thr Ala Pro Val Ser Leu Thr 515 520 525 Cys Pro Pro Gly Tyr His Gin He Asp Glu Val Met Asn He Ser Ala 530 535 540 His Pro His His Arg His Leu Ala Gly Val Gin Ser Thr Ser Gin Lys 545 550 555 560 Gly Tyr Ser His Gly His Lys Tyr Thr Pro Val He Ser Gin Pro Pro 565 570 575 Gin Pro Val Pro Val Val Ala Pro He Gin Gin Met Lys Cys He His 580 585 590 Ala Asn His Ala Pro Tyr Asn Leu He Cys Pro Val Gly Ser Arg Leu 595 600 605 Val Ala Asp Lys Cys Val Thr Tyr Ser Asp Lys He Cys Pro Asn Gly 610 615 620 Asn Cys Glu Arg He Tyr Asn Glu Pro Ala Glu Leu Val Cys Pro Pro 625 630 635 640 Gly Phe Ser Ser Ser Lys Pro He Gin Pro He Ser His Ser His He 645 650 655 Asn His Pro Asn Val Ser Val Pro Val Gin Pro Gin Thr He Asn Gin 660 665 670 Pro Gin Val He Gin Gin Arg Gin Val Asn Tyr Gin Pro Gin Val He 675 680 685 His Gin Thr Gin Glu He Leu Thr Thr Tyr Pro Thr Pro Val Tyr Gin 690 695 700 Thr Gly Thr He Tyr Gin Gly His His His His His His His His His 705 710 715 720 Arg Asn Leu Ala Ser Pro Glu Cys He Lys Thr He Ser Val Pro Tyr 725 730 735 He Leu Lys Cys Glu Ser Pro Phe He Leu Asp Gly Asp Lys Cys He 740 745 750 Glu Lys Thr Glu Lys He Cys Leu Gin Gly Asp Cys Arg Lys Gin Val 755 760 765 Val Val Piro Pro Thr Leu Ser Cys Pro Gin Gly Tyr Arg Asn Ala'Asn 770 775 780 Gly He 785

Claims: CLAIMS ' 1. A polypeptide in a substantially purified form comprising a contiguous sequence coded by a Cryptosporidium gene, said gene comprising a nucleotide sequence at least 50 % homologous to the sequence of SEQ ID No.l. 2. A polypeptide according to Claim 1 wherein said contiguous sequence comprises an antigenic determinant of Cryptosporidium. 3. A polypeptide according to any of previous claims wherein said contiguous sequence is coded by the sequence of SEQ ID No.l, or parts thereof. 4. A polypeptide according to Claim 3 wherein said contiguous sequence is comprised in the aminoacid sequence of SEQ ID No.2. 5. A diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, the polypeptide according to the invention. 6. Use of a polypeptide according to the invention for raising antibodies able to detect Cryptosporidium infection in biological and environmental samples. 7. An antibody obtained using as immunogen a polypeptide according to any of Claims from 1 to 4. 8. A diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, an antibody able to react with at least one polypeptide according to any of Claims from 1 to 4. 9. An oligonucleotide derived from a Cryptosporidium gene, said gene comprising a sequence at least 50 % homologous to the sequence of SEQ ID No.l. 10. An oligonucleotide according to Claim 9 having a sequence comprised in the sequence of SEQ ID No.l, or in the complementary strand of SEQ ID No. 1. 11. A diagnostic kit for the detection of Cryptosporidium in biological and environmental samples comprising, as specif ligand, the oligonucleotide according to Claim 9 or 10. 12. A PCR kit for the amplification of Cryptosporidium DNA comprising, as specif primer, at least one oligonucleotide according to Claim 9 or 10. 13. A PCR kit according to Claim 12 comprising, as specif primer, two oligonucleotides according to Claim 9 or 10.

Inventors: COLYZZI MARIO, CRISANTI ANDREA, GOMEZ MORALES MARIA ANGELES, LA ROSA GIUSEPPE, MULLER HANS MICHAEL, POZIO EDOARDO, RANUCCI LORELLA, RECKMANN INGEBORG, COLYZZI, MARIO, CRISANTI, ANDREA, GOMEZ MORALES, MARIA ANGELES, LA ROSA, GIUSEPPE, MULLER, HANS, MICHAEL, POZIO, EDOARDO, RANUCCI, LORELLA, RECKMANN, INGEBORG
Applicants: COLYZZI MARIO, CRISANTI ANDREA, GOMEZ MORALES MARIA ANGELES, IST SUPERIORE SANITA, MULLER HANS MICHAEL, POZIO EDOARDO, RANUCCI LORELLA, RECKMANN INGEBORG, ROSA GIUSEPPE, UNIV ROMA, IST SUPERIORE DI SANITA, UNIV ROMA "LA SAPIENZA"
Application year: 1993
Main classification: C12N15
IPC codes: C07K14, C12N15, C12Q1, G01N33